A study published in the Journal of Nuclear Medicine suggests a new fluorine-based PET agent may perform comparably and possibly better than FDG for oncology imaging. The agent 2-Deoxy-2-18F-fluoro-D-mannose, known as FDM, was assessed through in vitro and in vivo evaluations in small animals with AH109A tumor cells to examine uptake and metabolism of the agent. "F-18 FDM showed high accumulation in tumors, lower uptake in the brain than that of F-18 FDG, and rapid excretion from the blood, indicating promising characteristics for cancer imaging," researchers wrote.

Related Summaries